Moving towards Regulatory Harmonisation to enhance Access to Medicines in Africa

***********************************************************************************
Moving towards Regulatory Harmonisation to enhance Access to Medicines in Africa

***********************************************************************************
This is the 4th African Regulatory Conference (ARC) co-organised by the Drug Information Association (DIA) and the IFPMA’s African Regulatory Network (ARN).
IFPMA (International Federation of Pharmaceutical Manufacturers and Associations) represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 1.3 million employees strive to develop and provide innovative medicines, biological products, and vaccines that improve patients’ lives worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
The ARN is an ad-hoc network of the Regulatory Policy and Technical Standards Committee (RPTS) of IFPMA. The association works in partnership with regulatory authorities and the pharmaceutical industry in Africa to encourage greater harmonisation of regulatory requirements with the aim to help enable faster and expanded access to good quality innovative medicines for patients.
The ARC offers the opportunity for key stakeholders active in the region including Representatives from health authorities, local and multinational pharmaceutical companies, international, governmental and non-governmental organisations to exchange progressive views on key topics of interest and identify focus areas for ongoing efforts aimed to increase patient access to new and improved medicines.
Simultaneous translation in French and English will be available.
To view detailed programme please click on View PDF above.

----------------------------------------------------------------------------------------------------
What participants of the 3rd ARC said:
"A well placed conference which has fostered the sharing of information and best practices and openly discussion delegates regarding issues facing African Regulatory authorities and industry. Great job done."
"It’s the 3rd conference to attend. I appreciate the learning received in all ARC’s."
"The meeting is a very good platform of exchange and we have learned lessons which can help us when we are back in our country."

Featured Topics 

• African Medicines Regulatory Harmonisation (AMRH)
• Guidelines development and implementation
• Common technical documentation
• Submission requirements
• Dossier assessment
• End-to-end submission and approval process mapping
• Variations management
• Quality / Good Manufacturing Practices (GMP) / Inspections
• Transparency / Good Regulatory Practices
• Clinical trials capacity building

Who Should Attend 

Representatives of health authorities, regulatory affairs, quality assurance, medical, safety, research and development professionals, and other professionals involved in or interested in the aspects surrounding registration of medicinal products and regulatory harmonisation initiatives in Africa.

Learning Objectives 

Following the successful discussions held during the 3rd ARC in 2012 in Ghana, this edition intends to build on progress made within the region and to identify further initiatives for stakeholders to work together on the enhancement of healthcare in Africa.

This 4th ARC will provide an overview of regulatory harmonisation initiatives currently ongoing or emerging in Africa and will offer the opportunity to:

• Provide a platform to foster collaboration between African regulatory authorities and the pharmaceutical industry
• Share information and best practices
• Openly discuss issues faced by African regulatory authorities and industry
• Identify and agree on key proposals stemming from ARC discussions for further assessment and action

Strongly oriented towards informing on the current evolving regulatory landscape in Africa, and leveraging pragmatic and efficient approaches that strengthen ongoing harmonisation/convergence efforts, the conference will include panel discussions delivered during plenary and breakout sessions to maximise contributions from participants and enable deep-dived discussions of the key topics.

Special Offers 

Adjacent Events

26 April 2015

Training Courses:

• ICH endorsed Pharmacovigilance
• Common Technical Document / Quality

29 April 2015

IFPMA Workshop on Counterfeit medicines

Hotel & Travel 

Conference venueKing Fahd Palace Hotel
Pointe des Almadies
B.P. 8181, Dakar, Senegal
Tel: +221 33 869 69 69
www.kingfahdpalacehotels.com
The hotel booking can be made together with the conference registration.
Visa requirements
Please contact your local Senegal Embassy or Consulate for the most up-to-date information on visa requirements and how to apply for it if necessary.
For more information please visit: www.snedai.sn
Vaccinations
Please contact your GP for recommended vaccinations at least 4-8 weeks before travelling to Senegal.

Contact Information 

DIA has appointed Creative Trends to be the organising secretariat for the 4th African Regulatory Conference.
Registration
Creative Trends
Osu Forico Mall, Mission Street
Near Blue Gate, Osu
P.O. Box AN 15605
Accra-North, Ghana
Tel: +233 243 288 505
info@creativetrendsgh.com
Conference Programme
DIA Europe, Middle East & Africa
Kuechengasse 16
4051 Basel, Switzerland
Tel: +41 61 225 51 55
gunta.sveke@diaeurope.org
Exhibition
Roxann Schumacher
Tel: +41 61 225 51 38
roxann.schumacher@diaeurope.org

Program Committee 

Previous Next

Program Committee 1-3 of 13

Vincent I. Ahonkhai, MD, FAAFP

Senior Advisor, Global Health
Bill & Melinda Gates Foundation, United States

Corneille Traore

Director
West African Economic and Monetary Union (UEMOA) , Burkina Faso

Nouara Ait-Aider

Global Regulatory Affairs, RA ITC - Africa
Sanofi Aventis R&D, France

Program Committee 4-6 of 13

Arfan Ashraf

Manager: Global Regulatory Affairs - International
Amgen, United Kingdom

Fabienne Y. Benoist, PhD

Tropical Medicines Global Brand Regulatory Director
Novartis Pharma AG, Switzerland

Mercè Caturla

Global Access Regulatory Lead (WHO/Africa/MEWA/EAP)
Janssen Infectious Diseases, Belgium

Program Committee 7-9 of 13

Muriel Dona-Fologo

GTA IRC Africa chairperson
Sanofi, France

Osaretin Jaiyeola

Director, Regulatory Affairs - Sub-Saharan Africa
GlaxoSmithKline, Ghana

Robert Lebeda

Regulatory Affairs Manager
Eli Lilly GmbH, Austria

Program Committee 10-12 of 13

John Mwangi

Regulatory Affairs Specialist
Bayer Healthcare, Kenya

Sharmila Parsotam

Senior Director
Pfizer, United Kingdom

Dakshina Reddy

Director – DRA Head: South Africa and Southern Africa Group
Novartis South Africa (Pty) Ltd, South Africa

Program Committee 13-13 of 13

Myriam Sedrati

Regulatory Affairs Director North and West Africa
Merck Sharp & Dohme, Morocco

Agenda  

Day 1 Monday, Apr 27, 2015

• 7:30AM - 8:30AM (W. Central Africa Standard Time)

  REGISTRATION & WELCOME COFFEE
• 8:30AM - 9:15AM (W. Central Africa Standard Time)

  Session 1: Opening

  Speaker(s):

  • DIA Opening RemarksJytte Lyngvig, PhD
    Senior Vice President and Managing Director, DIA EMEA
    DIA Europe, Middle East and Africa, Switzerland
  • Keynote AddressRepresentative Invited
    Minister of Health
    Ministry of Health and Prevention
  • IFPMA / ARN IntroductionMuriel Dona-Fologo
    GTA IRC Africa chairperson
    Sanofi, France
  • Welcome Note by Partners and SponsorsVincent I. Ahonkhai, MD, FAAFP
    Senior Advisor, Global Health
    Bill & Melinda Gates Foundation, United States
  • Welcome Note by Partners and SponsorsAndreas Seiter
    Senior Health Specialist, Pharmaceuticals, Health, Nutrition & Population
    The World Bank, United States
• 9:15AM - 9:45AM (W. Central Africa Standard Time)

  Session 2: Plenary - Current regulatory landscape in Africa - Latest developments

  Speaker(s):

  • 2008-2014 ARC roadmapOsaretin Jaiyeola
    Director, Regulatory Affairs - Sub-Saharan Africa
    GlaxoSmithKline, Ghana
  • Vincent I. Ahonkhai, MD, FAAFP
    Senior Advisor, Global Health
    Bill & Melinda Gates Foundation, United States
  • Corneille Traore
    Director
    West African Economic and Monetary Union (UEMOA) , Burkina Faso
• 9:45AM - 10:30AM (W. Central Africa Standard Time)

  Session 3 Part 1: Plenary - Leveraging activities between regulatory agencies / bodies

  
  Session Chair(s):

  • Corneille Traore
    Director
    West African Economic and Monetary Union (UEMOA) , Burkina Faso

  This session will provide participants with an opportunity to get an update from regulatory agencies on the African Medicines Regulatory Harmonization (AMRH) programme. Key implementation learning amongst agencies and within the industry shall be shared in the 2nd part of the session.
  

  Speaker(s):

  • Representative Invited
    Senior Programme Officer for Health and Pharmaceuticals
    Southern African Development Community (SADC)
  • John Patrick Mwesigye
    Senior Health Officer (MRH)
    East African Community (EAC) Secretariat, Tanzania, United Republic of
  • Sybil Nana Ama Ossei-Agyeman-Yeboah
    Professional Officer in Charge, Essential Medicines and Vaccines
    West African Health Organisation (WAHO), Burkina Faso
  • Corneille Traore
    Director
    West African Economic and Monetary Union (UEMOA) , Burkina Faso
  • Representative Invited
    Director GMP
    Pharmacy and Poisons Board
  • Emilienne Yissibi Pola
    Public Health Pharmacist, Consultant HPPN/OCEAC
    Organisation of the fight against endemic diseases in central Africa (OCEAC), Cameroon
• 10:30AM - 11:00AM (W. Central Africa Standard Time)

  COFFEE BREAK & NETWORKING IN THE EXHIBITION AREA
• 11:00AM - 12:30PM (W. Central Africa Standard Time)

  Session 3 Part 2: Plenary - Leveraging activities between regulatory agencies / bodies

  
  Session Chair(s):

  • Corneille Traore
    Director
    West African Economic and Monetary Union (UEMOA) , Burkina Faso

  Speaker(s):

  • Samvel Azatyan, MD, PhD
    Group Lead, Capacity Building and Harmonization Support
    World Health Organization (WHO), Switzerland
  • Ricardo H. Cavazos Cepeda
    Chief of Staff
    Federal Commission for the Protection against Sanitary Risk (COFEPRIS), Mexico
  • Petra Doerr, PharmD
    Head of Communication and Networking, Deputy Director
    Swissmedic, Switzerland
  • William Mwatu
    Representative
    Kenya Association of the Pharmaceutical Industry (KAPI), Kenya
• 12:30PM - 2:00PM (W. Central Africa Standard Time)

  LUNCH & NETWORKING IN THE EXHIBITION AREA
• 2:00PM - 3:30PM (W. Central Africa Standard Time)

  Session 4: Workshop A - How to Reach One Dossier for All: Good review practices and regulatory convergence in Africa

  
  Session Chair(s):

  • Elliot P. Simonian
    Director, Emerging Markets, Global Regulatory Affairs
    GlaxoSmithKline, United Kingdom
  • Hiiti Baran Sillo
    Director General
    Tanzania Food and Drugs Authority (TFDA), Tanzania, United Republic of

  Moderator: Elliot P. Simonian
  Rapporteur: Hiiti Baran Sillo
  
  This session will be a panel discussion between regulatory agencies and the representatives of the industry. It is an opportunity to share and exchange the experiences of each counterpart (dossier preparation for the industries and dossier evaluation for the authorities)
  

  Speaker(s):

  • Amadou Moctar Dieye
    Director
    Direction de la Pharmacie et du Medicament, Senegal
• 2:00PM - 3:30PM (W. Central Africa Standard Time)

  Session 4: Workshop B - Improving GMP Compliance in Africa; The need to create an opportunity for pragmatic dialogue between MRA and industry

  
  Session Chair(s):

  • Carl Engleman
    Country Manager, Nigeria & East Africa Region
    Pfizer, United Arab Emirates

  Moderator: Carl Engleman
  Rapporteur: TBC
  
  How can we move towards a proactive, mutual process improvement of the current change control process across the African region such that supply continues without disruption and patients do not suffer when shortages are avoidable?
  

  Speaker(s):

  • Christa Wirthumer-Hoche, PhD
    Head of AGES
    Austrian Medicines and Medical Devices Agency, Austria
• 2:00PM - 3:30PM (W. Central Africa Standard Time)

  Session 4: Workshop C - Clinical Trials in Africa – Challenges and opportunities in building capacity

  
  Session Chair(s):

  • Kirti Narsai
    Director, Government Affairs and Policy
    Johnson & Johnson Medical, South Africa
  • Delese Mimi Darko
    Ag. DCE; Safety Monitoring & Clinical Trials Division
    Food and Drugs Authority, Ghana

  Moderator: Kirti Narsai
  Rapporteur: Delese Mimi Darko
  
  Participants will hear from regulators and industry about the status of clinical trials in Africa. The capacity building situation and its impact in multi-regional clinical trials, the role of the Regulators in reviewing the trial protocol to ensure safety for its population, the appropriateness of its scientific design, and that the protocol will be executed ethically will also be discussed
  

  Speaker(s):

  • Bartholomew Dicky Akanmori
    Assistant Regional Director
    Research & Development new Vaccines, Immunisation and Vaccines Development Progr, Congo, the Democratic Republic of the
  • Delese Mimi Darko
    Ag. DCE; Safety Monitoring & Clinical Trials Division
    Food and Drugs Authority, Ghana
  • Kirti Narsai
    Director, Government Affairs and Policy
    Johnson & Johnson Medical, South Africa
  • Thomas Nyirenda, MD, MS
    South-South Networking and Capacity Development Manager
    European & Developing Countries Clinical Trials Partnership (EDCTP), South Africa
• 3:30PM - 4:00PM (W. Central Africa Standard Time)

  COFFEE BREAK & NETWORKING IN THE EXHIBITION AREA
• 4:00PM - 4:30PM (W. Central Africa Standard Time)

  Session 4: Workshop A cont. - How to Reach One Dossier for All: Good review practices and regulatory convergence in Africa
• 4:00PM - 4:30PM (W. Central Africa Standard Time)

  Session 4: Workshop B cont. - Improving GMP Compliance in Africa; The need to create an opportunity for pragmatic partnering between MRA and industry
• 4:00PM - 4:30PM (W. Central Africa Standard Time)

  Session 4: Workshop C cont. - Clinical Trials in Africa – Challenges and opportunities in building capacity
• 4:30PM - 5:30PM (W. Central Africa Standard Time)

  Session 5: Plenary - Recap from parallel workshops, discussions and wrap-up

  Speaker(s):

  • Hiiti Baran Sillo
    Director General
    Tanzania Food and Drugs Authority (TFDA), Tanzania, United Republic of
  • Delese Mimi Darko
    Ag. DCE; Safety Monitoring & Clinical Trials Division
    Food and Drugs Authority, Ghana
  • Elliot P. Simonian
    Director, Emerging Markets, Global Regulatory Affairs
    GlaxoSmithKline, United Kingdom
  • Carl Engleman
    Country Manager, Nigeria & East Africa Region
    Pfizer, United Arab Emirates
  • Kirti Narsai
    Director, Government Affairs and Policy
    Johnson & Johnson Medical, South Africa
• 5:30PM - 7:00PM (W. Central Africa Standard Time)

  NETWORKING RECEPTION IN THE EXHIBITION HALL

Day 2 Tuesday, Apr 28, 2015

• 8:30AM - 9:00AM (W. Central Africa Standard Time)

  Session 6: Opening - Reflexions and Overview from Day One & Introduction to Day Two

  
  Session Chair(s):

  • Vincent I. Ahonkhai, MD, FAAFP
    Senior Advisor, Global Health
    Bill & Melinda Gates Foundation, United States
  • Corneille Traore
    Director
    West African Economic and Monetary Union (UEMOA) , Burkina Faso

  Speaker(s):

  • Fabienne Y. Benoist, PhD
    Tropical Medicines Global Brand Regulatory Director
    Novartis Pharma AG, Switzerland
  • Osaretin Jaiyeola
    Director, Regulatory Affairs - Sub-Saharan Africa
    GlaxoSmithKline, Ghana
• 9:00AM - 10:30AM (W. Central Africa Standard Time)

  Session 7: Plenary - Optimised Dossier Review Process

  
  Session Chair(s):

  • Milan Smid, MD, PhD
    Department of Essential Medicines and Health Products (EMP)
    World Health Organization (WHO), Switzerland

  Dossier review processes in different African countries are evolving over time and new registration requirements are being implemented. Variety and differences in requirements have led to increased review timelines and prolonged access for patients to medicines. This session targets to evaluate possibilities to optimise dossier review processes in different African regions and countries. Input will be brought in from the European Union where collaboration between countries has evolved and led to a harmonised approach and work-sharing between countries. The current situation in Africa will be analysed and recommendations be given how to improve processes, and show possibilities for harmonisation and collaboration between African countries.
  

  Speaker(s):

  • Aristide Ateba Etoundi
    Director of Pharmacy, Drugs and Laboratories
    Medicines and Laboratories at the Ministry of Public Health, Cameroon
  • Amadou Moctar Dieye
    Director
    Direction de la Pharmacie et du Medicament, Senegal
  • Margareth Ndomondo-Sigonda
    Pharmaceutical Coordinator
    The New Partnership For Africa's Development (NEPAD), South Africa
  • Christa Wirthumer-Hoche, PhD
    Head of AGES
    Austrian Medicines and Medical Devices Agency, Austria
• 10:30AM - 11:00AM (W. Central Africa Standard Time)

  COFFEE BREAK & NETWORKING IN THE EXHIBITION AREA
• 11:00AM - 12:00PM (W. Central Africa Standard Time)

  Session 8: Workshop D - New/Expedite Regulatory Pathways

  
  Session Chair(s):

  • Vincent I. Ahonkhai, MD, FAAFP
    Senior Advisor, Global Health
    Bill & Melinda Gates Foundation, United States
  • Milan Smid, MD, PhD
    Department of Essential Medicines and Health Products (EMP)
    World Health Organization (WHO), Switzerland

  Moderator: Vincent I. Ahonkhai
  Rapporteur: Milan Smid
  
  This session will give an overview of new / expedite regulatory pathways for medicines and vaccines, as well as analyse lessons learned from existing pathways: what could be replicated and what should be avoided. Opportunities and recommendations will be discussed.
  
• 11:00AM - 12:00PM (W. Central Africa Standard Time)

  Session 8: Workshop E - The Complex Journey of a Vaccine - Questions on access from a regulatory angle

  
  Session Chair(s):

  • Representative Invited
    Coordinator Regulatory Systems Strengthening (RSS)
    World Health Organization (WHO)

  Moderator: TBC
  Rapporteur: TBC
  
  This session will cover the availability of vaccines in Africa and the complex journey a vaccine has to make, from being manufactured to their assessment by regulatory bodies, and their availability to patients. The session will also include a discussion that will focus on how effective and efficient review processes and capacity building through convergence, co-operation and partnerships can improve access to vaccines and support the future needs of Africa.
  

  Speaker(s):

  • Representative Invited
    Senior Manager
    GSK Biologicals
  • Representative Invited
    Director GMP
    Pharmacy and Poisons Board
• 11:00AM - 12:00PM (W. Central Africa Standard Time)

  Session 8: Workshop F - Capacity Building – Training of medicines development and regulatory sciences in emerging countries

  Speaker(s):

  • Alexander Dodoo, PhD
    Director
    Centre for Tropical Clinical Pharmacology & Therapeutics, Ghana
  • Sandor Kerpel-Fronius
    Project Academic Leader
    Cooperative European Medicines Development Course (CEMDC), Hungary
  • Margareth Ndomondo-Sigonda
    Pharmaceutical Coordinator
    The New Partnership For Africa's Development (NEPAD), South Africa
  • Paul B. Orhii
    Director General
    National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria
• 12:00PM - 12:30PM (W. Central Africa Standard Time)

  Session 9: Plenary - Recap from parallel workshops

  Speaker(s):

  • Milan Smid, MD, PhD
    Department of Essential Medicines and Health Products (EMP)
    World Health Organization (WHO), Switzerland
  • Vincent I. Ahonkhai, MD, FAAFP
    Senior Advisor, Global Health
    Bill & Melinda Gates Foundation, United States
• 12:30PM - 2:00PM (W. Central Africa Standard Time)

  LUNCH & NETWORKING IN THE EXHIBITION AREA
• 2:00PM - 3:30PM (W. Central Africa Standard Time)

  Session 10: Workshop G - Regulators' closed panel discussion

  
  Session Chair(s):

  • Samvel Azatyan, MD, PhD
    Group Lead, Capacity Building and Harmonization Support
    World Health Organization (WHO), Switzerland
  • Amadou Moctar Dieye
    Director
    Direction de la Pharmacie et du Medicament, Senegal

  Moderator: Samvel Azatyan
  Rapporteur: Amadou Moctar Dieye
  
  This session is set-up as a panel discussion with regulators representatives only. Main discussion points, comments and recommendations from this session as recorded by a rapporteur will be shared during next plenary session. Regulators’ views of needs and opportunities for improvement related to the discussion points will be brought into perspective with each other during the session.
  

  Discussant(s):

  • Ricardo H. Cavazos Cepeda
    Chief of Staff
    Federal Commission for the Protection against Sanitary Risk (COFEPRIS), Mexico
  • Petra Doerr, PharmD
    Head of Communication and Networking, Deputy Director
    Swissmedic, Switzerland
  • Representative Invited
    Senior Programme Officer for Health and Pharmaceuticals
    Southern African Development Community (SADC)
  • John Patrick Mwesigye
    Senior Health Officer (MRH)
    East African Community (EAC) Secretariat, Tanzania, United Republic of
  • Margareth Ndomondo-Sigonda
    Pharmaceutical Coordinator
    The New Partnership For Africa's Development (NEPAD), South Africa
  • Sybil Nana Ama Ossei-Agyeman-Yeboah
    Professional Officer in Charge, Essential Medicines and Vaccines
    West African Health Organisation (WAHO), Burkina Faso
  • Estelle Taute
    Director: Operations and Administration
    Medicines Regulatory Authority, South Africa
  • Corneille Traore
    Director
    West African Economic and Monetary Union (UEMOA) , Burkina Faso
  • Representative Invited
    Director GMP
    Pharmacy and Poisons Board
  • Christa Wirthumer-Hoche, PhD
    Head of AGES
    Austrian Medicines and Medical Devices Agency, Austria
  • Emilienne Yissibi Pola
    Public Health Pharmacist, Consultant HPPN/OCEAC
    Organisation of the fight against endemic diseases in central Africa (OCEAC), Cameroon
• 2:00PM - 3:30PM (W. Central Africa Standard Time)

  Session 10: Workshop H - Industry and Stakeholders’ closed panel discussion

  
  Session Chair(s):

  • Sharon N. Olmstead
    Global Head, Development and Regulatory Policy
    Novartis Pharmaceuticals Corporation, United States
  • Mercè Caturla
    Global Access Regulatory Lead (WHO/Africa/MEWA/EAP)
    Janssen Infectious Diseases, Belgium
  • William Mwatu
    Representative
    Kenya Association of the Pharmaceutical Industry (KAPI), Kenya

  Moderator: Sharon Olmstead
  Co-Moderator: Merce Caturla
  Rapporteur: William Mwatu
  
  This session is set-up as a panel discussion with industry representatives only. Main discussion points, comments and recommendations from this session as recorded by a rapporteur will be shared during next plenary session. Industry’s views of needs and opportunities for improvement related to the discussion points will be brought into perspective during the session.
  

  Discussant(s):

  • Carl Engleman
    Country Manager, Nigeria & East Africa Region
    Pfizer, United Arab Emirates
  • Representative Invited
    Senior Director
    Pfizer
  • Representative Invited
    Senior Manager
    GSK Biologicals
  • Elliot P. Simonian
    Director, Emerging Markets, Global Regulatory Affairs
    GlaxoSmithKline, United Kingdom
• 3:30PM - 4:00PM (W. Central Africa Standard Time)

  COFFEE BREAK & NETWORKING IN THE EXHIBITION AREA
• 4:00PM - 4:45PM (W. Central Africa Standard Time)

  Session 11: Plenary - Recap from parallel workshops

  Speaker(s):

  • Amadou Moctar Dieye
    Director
    Direction de la Pharmacie et du Medicament, Senegal
  • William Mwatu
    Representative
    Kenya Association of the Pharmaceutical Industry (KAPI), Kenya
  • Mercè Caturla
    Global Access Regulatory Lead (WHO/Africa/MEWA/EAP)
    Janssen Infectious Diseases, Belgium
  • Samvel Azatyan, MD, PhD
    Group Lead, Capacity Building and Harmonization Support
    World Health Organization (WHO), Switzerland
  • Sharon N. Olmstead
    Global Head, Development and Regulatory Policy
    Novartis Pharmaceuticals Corporation, United States
• 4:45PM - 6:30PM (W. Central Africa Standard Time)

  Session 12: Closing - Challenges/barriers to access medicines

  
  Session Chair(s):

  • Vincent I. Ahonkhai, MD, FAAFP
    Senior Advisor, Global Health
    Bill & Melinda Gates Foundation, United States

Exhibits  

This conference gives the opportunity to a limited number of organisations to present themselves to the key stakeholders in the field through 6 sqm mini-booths.
Exhibitors are granted a unique opportunity to meet attendees before and after sessions and during all breaks. As there are only a very limited number of booths available, high visibility can be guaranteed. The mini-booths will be positioned to fit naturally into the flow of conference traffic, so the opportunities to engage with attendees are ensured.
ARC Exhibitor Application Form
For more details, please contact Roxann Schumacher, Exhibits Manager at roxann.schumacher@diaeurope.org or call +41 61 225 51 38.

Registration Fees 

Other Fees

Government/Nonprofit/Academia Overseas

€350.00

Industry Overseas

€1500.00

Government/Nonprofit/Academia Africa

€220.00

Industry Africa

€650.00

Registration Information Registration fee includes conference delegate material, refreshments and lunches.